Pachychoroid Spectrum Disease: Comparison of Patients with Central Serous Chorioretinopathy Complicated with Pachychoroid Neovasculopathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to determine the incidence and visual outcomes of pachychoroid neovasculopathy (PNV) in patients initially diagnosed with central serous chorioretinopathy (CSC). Methods: In this study, 144 patients aged 20 to 55 years with treatment-naive chronic CSC, defined as the persistence of subretinal fluid (SRF) for ≥6 months, were retrospectively enrolled. Patients with PNV at the initial evaluation were categorized as group 1, whereas those who developed new-onset PNV during follow-up were categorized as group 2. Patients without PNV until the end of the follow-up were categorized as group 3. Results: Over a mean follow-up period of 49.9 ± 39.9 months, new-onset PNV was diagnosed in 11.8% of patients with CSC. The time taken to reach the initial resolution was longest in group 1 (group 1, 11.13 ± 10.70 months; group 2, 8.14 ± 7.90 months; group 3, 7.32 ± 9.55 months), although these differences were not statistically significant. The numbers of injections needed to achieve initial resolution were 3.76 ± 5.90, 1.64 ± 2.06, and 1.74 ± 4.33 in groups 1, 2, and 3, respectively, with no significant differences. SRF recurrence was recorded in seven patients (29.2%) in group 1, nine (64.3%) in group 2, and 28 (26.7%) in group 3. The recurrence rates were significantly higher in group 2 than those in group 1 or 3. At the end of the follow-up period, significant improvements in best-corrected visual acuity were achieved in groups 1 and 3, compared with baseline, but not in group 2. Conclusions: Patients with chronic CSC with new-onset PNV exhibited higher SRF recurrence and worse visual outcomes compared to those with initial PNV or those with chronic CSC without PNV. Our study emphasizes the importance of routine screening for prompt diagnoses of new-onset PNV in individuals with chronic CSC.
Abstract
Purpose: This study aimed to determine the incidence and visual outcomes of pachychoroid neovasculopathy (PNV) in patients initially diagnosed with central serous chorioretinopathy (CSC). Methods: In this study, 144 patients aged 20 to 55 years with treatment-naive chronic CSC, defined as the persistence of subretinal fluid (SRF) for ≥6 months, were retrospectively enrolled. Patients with PNV at the initial evaluation were categorized as group 1, whereas those who developed new-onset PNV during follow-up were categorized as group 2. Patients without PNV until the end of the follow-up were categorized as group 3. Results: Over a mean follow-up period of 49.9 ± 39.9 months, new-onset PNV was diagnosed in 11.8% of patients with CSC. The time taken to reach the initial resolution was longest in group 1 (group 1, 11.13 ± 10.70 months; group 2, 8.14 ± 7.90 months; group 3, 7.32 ± 9.55 months), although these differences were not statistically significant. The numbers of injections needed to achieve initial resolution were 3.76 ± 5.90, 1.64 ± 2.06, and 1.74 ± 4.33 in groups 1, 2, and 3, respectively, with no significant differences. SRF recurrence was recorded in seven patients (29.2%) in group 1, nine (64.3%) in group 2, and 28 (26.7%) in group 3. The recurrence rates were significantly higher in group 2 than those in group 1 or 3. At the end of the follow-up period, significant improvements in best-corrected visual acuity were achieved in groups 1 and 3, compared with baseline, but not in group 2. Conclusions: Patients with chronic CSC with new-onset PNV exhibited higher SRF recurrence and worse visual outcomes compared to those with initial PNV or those with chronic CSC without PNV. Our study emphasizes the importance of routine screening for prompt diagnoses of new-onset PNV in individuals with chronic CSC.
참고문헌 (36)
- Pang CE, "Pachychoroid neovasculopathy", Retina, 35, pp.1~9 (2015)
- Yanagi Y, "Pachychoroid disease : a new perspective on exudative maculopathy", Jpn J Ophthalmol, 64, pp.323~337 (2020)
- Cheung CM, "Pachychoroid disease", Eye(Lond), 33, pp.14~33 (2019)
- Siedlecki J, "The pachychoroid disease spectrum-and the need for a uniform classification system", Ophthalmol Retina, 3, pp.1013~1015 (2019)
- Akkaya S, "Spectrum of pachychoroid diseases", Int Ophthalmol, 38, pp.2239~2246 (2018)
- Carosielli M, "Intravitreal brolucizumab for pachychoroid neovasculopathy associated with chronic central serous chorioretinopathy", Transl Vis Sci Technol, 12, pp.17~ (2023)
- Mazzeo TJ, "Pachychoroid disease spectrum : review article", Graefes Arch Clin Exp Ophthalmol, 260, pp.723~735 (2022)
- Mrejen S, "Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy", Ophthalmology, 126, pp.576~588 (2019)
- Zhou X, "Risk factors and characteristics of central serous chorioretinopathy with later development of macular eovascularization detected on OCT angiography : a retrospective multicentre observational study", BMJ Open Ophthalmol, 7, pp.e000976~ (2022)
- Sulzbacher F, "Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy(CSC)diagnosed by swept source optical coherence tomography angiography(SS OCTA)", Graefes Arch Clin Exp Ophthalmol, 257, pp.1581~1590 (2019)
- Dansingani KK, "En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography", Retina, 36, pp.499~516 (2016)
- Gallego-Pinazo R, "Pachychoroid diseases of the macula", Med Hypothesis Discov Innov Ophthalmol, 3, pp.111~115 (2014)
- Sartini F, "Pachychoroid neovasculopathy:a type-1 choroidal neovascularization belonging to the pachychoroid spectrum: pathogenesis, imaging and available treatment options", Int Ophthalmol, 40, pp.3577~3589 (2020)
- Schworm B, "Ranibizumab non-response in pachychoroid neovasculopathy : effects of switching to aflibercept", Sci Rep, 10, pp.8439~ (2020)
- Matsumoto H, "Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration", Jpn J Ophthalmol, 62, pp.144~150 (2018)
- Lai TY, "Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause : twelve-month results of the MINERVA study", Retina, 38, pp.1464~1477 (2018)
- Matsumoto H, "One-year outcomes of half-f luence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions", Jpn J Ophthalmol, 64, pp.203~209 (2020)
- Hata M, "Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes", Ophthalmol Retina, 3, pp.1016~1025 (2019)
- Guyer DR, "Digital indocyanine green videoangiography of central serous chorioretinopathy", Arch Ophthalmol, 112, pp.1057~1062 (1994)
- Loo RH, "Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy", Retina, 22, pp.19~24 (2002)
- Shiragami C, "Clinical features of central serous chorioretinopathy with type 1 choroidal neovascularization", Am J Ophthalmol, 193, pp.80~86 (2018)
- Lee GI, "Risk factors and outcomes of choroidal neovascularization secondary to central serous chorioretinopathy", Sci Rep, 9, pp.3927~ (2019)
- Peiretti E, "Choroidal neovascularization in Caucasian patients with longstanding central serous chorioretinopathy", Retina, 35, pp.1360~1367 (2015)
- Romano MR, "An international collaborative evaluation of central serous chorioretinopathy:different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study", Acta Ophthalmol, 98, pp.e549~e558 (2020)
- Jin C, "Argon laser photocoagulation in the treatment of central serous chorioretinopathy", Yan Ke Xue Bao, 10, pp.227~231 (1994)
- Novak MA, "Krypton and argon laser photocoagulation for central serous chorioretinopathy", Retina, 7, pp.162~169 (1987)
- Spaide RF, "Treatment of polypoidal choroidal vasculopathy with photodynamic therapy", Retina, 22, pp.529~535 (2002)
- Kwon JM, "One-year results of aflibercept treatment for polypoidal choroidal vasculopathy with good visual acuity", Korean J Ophthalmol, 35, pp.26~36 (2021)
- Peiretti E, "Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy", Retina, 38, pp.1526~1532 (2018)
- Karasu B, "Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy", Cutan Ocul Toxicol, 41, pp.145~154 (2022)
- Hata M, "Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration", Invest Ophthalmol Vis Sci, 58, pp.292~298 (2017)
- Spaide RF, "Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization", Am J Ophthalmol, 160, pp.6~16 (2015)
- Sacconi R, "Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy : a OCT-angiography study", Eye(Lond), 33, pp.1809~1817 (2019)
- Yoon J, "Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy", Sci Rep, 11, pp.12052~ (2021)
- Yeo JH, "Choroidal neovascularization secondary to central serous chorioretinopathy : OCT angiography findings and risk factors", J Ophthalmol, 2020, pp.7217906~ (2020)
- Miere A, "Optical coherence tomography angiography features of subretinal fibrosis in age-related macular degeneration", Retina, 35, pp.2275~2284 (2015)